Czech-based Mewery has introduced a prototype of microalgae-based cultivated meat, combining 75 percent pork cells and 25 percent microalgae cells.
The scientific team of Mewery, a cell-based food tech start-up, , cultivated this prototype in 10 weeks.
According to Mewery founder, Roman Lauš, they already have several variants that work for them without animal products and which they continue to work with.
The addition of microalgae improves the product's nutritional value by providing vitamins, antioxidants, minerals, fiber, and vital fatty acids.
Mewery hopes to have the finished product available for sale in two years. Once the necessary legislation is ready, consumers will have access to it.


Asian Fund Managers Turn More Optimistic on Growth but Curb Equity Return Expectations: BofA Survey
Lab-grown meat: you may find it icky, but it could drive forward medical research
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life
Asian Currencies Slip as Dollar Strengthens; Indian Rupee Rebounds on Intervention Hopes
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 



